AACR 2024: PDC*line Pharma presents interim clinical results

Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC*lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and...

Related Keywords

France , Switzerland , Germany , Belgium , Netherlands , Leuven , Region Flamande , United States , Poland , American , Johan Vansteenkiste , Eric Halioua , American Association For Cancer Research , Non Small Cell Lung Cancer , American Association , Cancer Research , Annual Meeting , Low Dose , High Dose , Objective Response Rate , Progression Free Survival , Adverse Events , Partial Response , Stable Disease , Best Objective Response , Disease Control Rate , Not Reached , Prof Johan Vansteenkiste , Safety Monitoring Board , Beatrice De Vos , Plasmacytoid Dendritic Cells , Peripheral Blood Mononuclear Cells ,